Provided by Tiger Trade Technology Pte. Ltd.

PagerDuty, Inc.

6.01
-0.3000-4.75%
Post-market: 6.030.0200+0.33%19:55 EDT
Volume:2.51M
Turnover:15.15M
Market Cap:510.73M
PE:3.21
High:6.25
Open:6.21
Low:5.92
Close:6.31
52wk High:18.97
52wk Low:5.92
Shares:84.98M
Float Shares:80.63M
Volume Ratio:0.85
T/O Rate:3.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.87
EPS(LYR):1.87
ROE:82.50%
ROA:0.48%
PB:2.01
PE(LYR):3.21

Loading ...

Wrap Technologies announces BolaWrap 150 integration at Glenwood Springs PD

TIPRANKS
·
Jan 12

Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases

GlobeNewswire
·
Jan 12

HENLIUS (02696) Surges Over 5% Intraday as Company Unveils First Phase II Clinical Data for PD-L1 ADC in Esophageal Squamous Cell Carcinoma

Stock News
·
Jan 08

Truist Securities Adjusts Price Target on PagerDuty to $16 From $20, Maintains Buy Rating

MT Newswires Live
·
Jan 07

PagerDuty Is Maintained at Buy by Truist Securities

Dow Jones
·
Jan 07

Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

GlobeNewswire
·
Jan 06

NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer

GlobeNewswire
·
Jan 06

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development

GlobeNewswire
·
Jan 06

Has PagerDuty (PD) Become a Potential Opportunity After Prolonged Share Price Weakness

Simply Wall St.
·
Jan 06

PagerDuty Shares Lower After RBC Downgrade

MT Newswires Live
·
Jan 06

Tasly: PD-L1/VEGF Bispecific Antibody's Solid Tumor Indication Phase IIa and Colorectal Cancer Indication Phase IIb Trials Currently Enrolling Patients

Deep News
·
Jan 05

Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors

GlobeNewswire
·
Jan 05

RBC Downgrades PagerDuty to Sector Perform From Outperform, Cuts Price Target to $15 From $17

MT Newswires Live
·
Jan 05

SKB BIO-B (06990) Core Product TROP2 ADC Sac-TMT Combined with Immunotherapy Pembrolizumab Receives NMPA Breakthrough Therapy Designation for First-Line Treatment of PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Stock News
·
Jan 05

PagerDuty Director Dan Alexandru Solomon Reports Sale of Common Shares

Reuters
·
Jan 01

The Bull Case For PagerDuty (PD) Could Change Following Retention Pressures And A Securities Probe

Simply Wall St.
·
Dec 20, 2025

PagerDuty (PD) Valuation After Shareholder Investigation and Cut to Retention and Revenue Outlook

Simply Wall St.
·
Dec 18, 2025

SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

GlobeNewswire
·
Dec 17, 2025

Annovis to Host Corporate Update Webinar on January 28, 2026

GlobeNewswire
·
Dec 16, 2025

Beijing Konruns Pharmaceutical (603590.SH) Completes First Patient Enrollment in Phase II Clinical Trial of KC1036 Combined with PD-1 Antibody and Platinum-Based Chemotherapy for Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Stock News
·
Dec 15, 2025